Repatha (Evolocumab) Regulatory Status: US, EU, Canada, and UK Approvals

Evolocumab (brand name Repatha, made by Amgen) is a fully human monoclonal antibody that inhibits PCSK9, an enzyme that normally degrades LDL receptors on liver cells. It is approved as a prescription-only injectable in the United States, the European Union, Canada, and the United Kingdom, for familial hypercholesterolemia and, in the US and EU, for cardiovascular risk reduction in adults with established atherosclerotic disease. Regulatory approval in all four jurisdictions is well established. What is not established, and is easy to miss, is that formal approval of an indication does not by itself determine whether a public payer, an NHS commissioner, or a private US insurer will actually pay for it: every jurisdiction reviewed here layers additional LDL-C thresholds and step-therapy requirements on top of the label.

What evolocumab is approved for, and what that does not guarantee

The useful question for most readers is not "is Repatha approved" but "does approval mean I can get it." The answer is that approval sets the outer boundary of legal use; a separate layer of health-technology-assessment and payer policy decides who within that boundary is actually reimbursed. That second layer is usually stricter than the label, and it differs by country and, within Canada and the US, by province or plan.

How evolocumab lowers LDL cholesterol

PCSK9 is a protein that binds LDL receptors on hepatocytes and marks them for degradation, reducing the liver's ability to clear LDL cholesterol from the blood. Evolocumab binds circulating PCSK9 and prevents it from degrading the receptor, so more LDL receptors remain available to clear LDL-C. This mechanism was established through genetic studies of PCSK9 gain- and loss-of-function variants published in the early-to-mid 2000s, which showed that people with naturally low PCSK9 activity have lifelong low LDL-C and lower coronary heart disease risk. That genetic evidence is the accepted rationale for pharmacologic PCSK9 inhibition, though the exact original studies should be checked against the primary literature by a clinical reviewer rather than assumed from secondary summaries.

Evolocumab is given by subcutaneous injection using a prefilled autoinjector or prefilled syringe, at either 140 mg every two weeks or 420 mg (three 140 mg injections) once monthly. Trial data cited in regulatory submissions describe LDL-C reductions in the range of roughly 55 to 60 percent when evolocumab is added to statin therapy; this is a trial-evidence figure from the original approval package and should be treated as an approximate, label-supported range rather than an individual prediction.

United States: FDA approval and what it added over time

The FDA approved evolocumab in 2015 for adults with heterozygous familial hypercholesterolemia and for those with clinical atherosclerotic cardiovascular disease who need additional LDL-C lowering beyond diet and maximally tolerated statin therapy, with a parallel approval for homozygous familial hypercholesterolemia in patients 13 and older. Full current prescribing information, including the approved population and dosing, is available directly from the FDA label (FDA label).

In December 2017 the FDA expanded the label to include reduction of cardiovascular risk (heart attack, stroke, and coronary revascularization) in adults with established atherosclerotic disease, based on outcomes data from the FOURIER trial (see below). This is a genuine label expansion, not an off-label extrapolation: cardiovascular risk reduction is now an FDA-approved indication, not just an LDL-lowering claim.

No boxed warning appears on the current label. Injection site reactions are the most commonly reported adverse event in trial data submitted to the FDA. No dose adjustment is described for renal or hepatic impairment, age, sex, or race in the label's pharmacokinetic summary, though this is a general population statement, not a substitute for individualized prescribing judgment.

Decision map: what actually determines whether you can get Repatha

Readers usually arrive at this page with one of three different questions, and each has a different answer depending on jurisdiction. Use this to figure out which question you actually have, and what evidence tier answers it.

The exception that trips people up most often: a person can meet every criterion on the drug label and still be denied first-line coverage, because payer policy in every jurisdiction reviewed here sits closer to "guideline-recommended add-on after statin plus ezetimibe fails" than to the label's broader wording. The practical next step is to ask a prescriber to document the specific LDL-C value and prior therapy failures your plan or health system requires, rather than to rely on the drug being "approved" as proof of coverage.

European Union: EMA marketing authorization

The European Medicines Agency authorized evolocumab in 2015 through the centralized procedure, which grants a single authorization valid across EU member states plus Iceland, Liechtenstein, and Norway (EMA EPAR). The approved EU indications cover primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia as an add-on to statin or other lipid-lowering therapy, or as monotherapy in patients who are statin-intolerant or for whom statins are contraindicated, plus homozygous familial hypercholesterolemia in patients 12 and older. The EMA updated the product information after FOURIER was published to reflect cardiovascular outcomes evidence, in addition to the original LDL-lowering indication. Readers should check the linked EPAR page directly for the current status, since EU product information can be amended after initial authorization.

United Kingdom: MHRA authorization and NICE access criteria

Following the UK's departure from the EU regulatory framework on January 1, 2021, the MHRA converted the existing EU marketing authorization into a Great Britain authorization. Evolocumab remains a legally marketed medicine in the UK on that basis.

Separately, NICE Technology Appraisal 394 sets the criteria under which NHS England will fund evolocumab, restricting it to patients whose LDL-C remains above specific thresholds despite maximal tolerated lipid-lowering therapy (NICE TA394). This is a coverage decision made by a health technology assessment body, not a statement about whether the drug is approved; MHRA authorization and NICE funding criteria are two separate layers, and a patient can be a legitimate candidate under the marketing authorization while falling outside NICE's funding threshold. Readers should check the current NICE guidance page directly, since thresholds and NHS commissioning arrangements have been revisited since the original 2016 appraisal and this page cannot guarantee it reflects the latest version.

Canada: Health Canada authorization and provincial reimbursement

Health Canada authorized evolocumab in 2015 (Health Canada Drug Product Database), with an indication set broadly similar to the US label: heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia in patients 13 and older, and primary hyperlipidemia requiring additional LDL-C lowering. As in the UK, provincial drug plans layer their own reimbursement criteria on top of the federal authorization, and these criteria vary by province and change over time; a reader in Canada should confirm current provincial formulary rules directly with their plan rather than assume national approval implies provincial coverage.

The FOURIER trial and what it does and does not show

FOURIER is the large cardiovascular outcomes trial that supports evolocumab's cardiovascular risk-reduction indication in the US and the updated EU product information. It enrolled adults with established atherosclerotic cardiovascular disease who were already on statin therapy, and it is widely reported as showing a reduction in the composite of cardiovascular death, myocardial infarction, stroke, and related events over roughly two years of follow-up, with a larger relative reduction in the harder secondary endpoint of cardiovascular death, MI, or stroke. Because the specific hazard ratios and confidence intervals attributed to this trial in secondary summaries are easy to transcribe incorrectly, a clinician or medical reviewer should confirm the exact figures against the original New England Journal of Medicine publication before they are used in patient-facing material or restated as precise numbers. The trial population is important: FOURIER studied secondary prevention in people already on statins, not primary prevention, and its results should not be generalized to patients who have never tried a statin or who do not have established atherosclerotic disease.

A longer-term open-label extension of FOURIER has been reported to show continued cardiovascular benefit and no new safety signal with several years of additional exposure at very low LDL-C levels, but again the specific numeric claims from that extension should be verified against the primary publication rather than treated as settled fact on this page.

Guideline positioning: recommendations are not the same as approval or coverage

Major cardiology societies in the US, Europe, and Canada have incorporated PCSK9 inhibitors into cholesterol management guidelines as an add-on for patients at high or very high cardiovascular risk who remain above target LDL-C on maximally tolerated statin plus ezetimibe. European guidance has generally set lower LDL-C targets than US guidance, which is one reason PCSK9 inhibitor use is recommended somewhat more readily in some European guideline documents than in the corresponding US ones. These are guideline recommendations, a distinct evidence tier from FDA/EMA approval and from payer coverage policy; a strong guideline recommendation does not guarantee that a specific insurer, provincial plan, or NHS commissioner will fund the drug at that same threshold. Readers should treat any specific numeric LDL-C target cited from a guideline as needing verification against the current version of that guideline, since thresholds have shifted across guideline revisions.

Cost and exclusivity: dated information that changes

Amgen reduced the US list price of evolocumab substantially in 2018, a change that was widely reported at the time in the context of cost-effectiveness analyses questioning the drug's original price. Exact current list price, formulary tier, and copay assistance availability should be confirmed directly with Amgen or a pharmacy benefit source, since list prices and coverage terms change and this page cannot guarantee current accuracy as of any specific reader's visit. Evolocumab's biologic reference-product exclusivity in the US is generally described as running for 12 years from initial approval, which would place expiry around 2027, but a biosimilar's actual market entry also depends on separate FDA approval of that biosimilar and does not follow automatically once exclusivity lapses. No evolocumab biosimilar had received approval in a major market as of the last review of this page; this status should be re-checked periodically, since it will change.

Practical safety and administration notes

Storage requires refrigeration at 2 to 8 degrees Celsius, with allowance for a single period at room temperature (up to 25 degrees Celsius) for up to 30 days before use; once warmed, the product should not be returned to the refrigerator. Injection sites are the abdomen, thigh, or upper arm. This is general administration information from the product label, not individualized dosing guidance, and a prescriber or pharmacist should confirm handling instructions for a specific patient's prescription.

Anyone experiencing signs of a serious allergic reaction after an injection, such as difficulty breathing, swelling of the face or throat, or a widespread rash, needs urgent medical evaluation rather than waiting for a routine follow-up appointment.

What is established, what is plausible, and what is not established

Established: evolocumab has active marketing authorization in the US, EU, Canada, and UK; it is FDA- and EMA-approved for familial hypercholesterolemia and, with updated label language, for cardiovascular risk reduction in adults with established atherosclerotic disease already on statins; its mechanism of PCSK9 inhibition and consequent LDL receptor recycling is well characterized.

Plausible but requiring current verification: the specific numeric magnitude of cardiovascular benefit reported from FOURIER and its open-label extension, current list prices and payer step-therapy thresholds, and the precise current wording of NICE and provincial Canadian coverage criteria, all of which change over time and should be confirmed against a primary or current official source before being repeated as fact.

Not established from the material reviewed here: that guideline-recommended use in any one region translates directly into insurance or NHS approval for an individual patient, that evolocumab's cardiovascular benefit extends to primary prevention populations, or that a biosimilar timeline can be predicted with confidence beyond the stated exclusivity period.